Eyenovia, Inc. is a biotechnology and pharmaceutical company focused on developing innovative ophthalmic treatments using micro-interventional robotic technology.

# Company Summary: Eyenovia, Inc.

### Overview
Eyenovia, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing ophthalmic treatments. The company specializes in innovative drug delivery systems for eye diseases, leveraging micro-interventional robotics and smart topical therapeutics.

### Business Focus
- Development of ophthalmic pharmaceuticals utilizing micro-interventional robotic technology.
- Focus on treatments for various eye conditions, potentially including glaucoma, age-related macular degeneration, diabetic retinopathy, and other ocular diseases.
- Integration of proprietary technologies such as micro-dose delivery systems and micro-robotics in ophthalmology.

### Financial and Operational Highlights (based on filing data, not recent or forward-looking)
- As of April 23, 2025:
  - **Number of Outstanding Shares:** 2,830,546
  - **Market Capitalization:** Approximately $32.5 million (based on last trading price of $47.52 on June 30, 2024, adjusted for a 1-for-80 reverse stock split effected on January 31, 2025)
- **Employees:** The filing does not specify the exact number of employees.
- **Customers:** The company does not provide specific information about the number of customers served.
- **Revenue and Income:** The filing does not provide specific financial figures such as revenue or net income.

### Corporate Structure and Management
- **CEO and President:** Michael Rowe
- **Other Key Executives:** Bren Kern (Chief Operating Officer), John P. Gandolfo (former CFO), Andrew Jones (former CFO)
- **Board of Directors:** Consists of seven members with experience in biotech, finance, ophthalmology, and global business development:
  - Charles E. Mather IV (Chairman)
  - Tsontcho Ianchulev, M.D., M.P.H.
  - Michael Geltzeiler
  - Rachel Jacobson
  - Ram Palanki, Pharm.D.
  - Ellen Strahlman, M.D.
  - Michael Rowe (also an executive officer)

### Notable Details
- No specific customer counts, revenue, or income figures are included in the filing.
- The company emphasizes innovation in ophthalmic drug delivery and has a focus on life sciences and biotech sectors.
- The company's business model includes a combination of development and, potentially, commercialization of ophthalmic products using cutting-edge technology.

*Note: The provided document is primarily an SEC filing (Form 10-K/A) with corporate governance, executive compensation, and stock ownership details. It does not contain specific financial performance metrics such as revenue, net income, or customer base.*

Eyenovia, Inc. is a clinical-stage biopharmaceutical company focused on developing microdose therapeutics for ophthalmic conditions.

# Eyenovia, Inc.

## Business focus
Eyenovia is a clinical-stage biopharmaceutical company developing and commercializing proprietary microdose therapeutics for ophthalmic indications. The company uses its Microdose delivery technology to administer low-volume eye drops intended to improve treatment adherence and reduce side effects.

## Key products and technologies
- Microdose technology: a proprietary system designed to dispense low-volume eye drops.
- Product candidates:
  - MydCom — an eye drop for mydriasis (pupil dilation) during ophthalmic exams.
  - Vivo — a potential treatment for conditions such as myopia and presbyopia, using atropine sulfate and pilocarpine solutions.

## Market position
Eyenovia operates in the ophthalmology market, engaging with healthcare providers for clinical trials and potential partnerships. Its products are primarily targeted at healthcare professionals, reflecting a business-to-business model ahead of broader patient access.

## Financial and operational highlights
- Employees: approximately 35.
- Revenue: as of December 31, 2023, Eyenovia had not recorded material product sales revenue and remains focused on research, development, and clinical trials.
- Financial status: the company continues to invest in clinical R&D and has raised capital through equity financings. The market value of Eyenovia's common stock is approximately $88 million.

## Headquarters and corporate details
- Address: 295 Madison Avenue, Suite 2400, New York, NY 10017.
- Corporate structure: Delaware corporation.
- Public listing: Nasdaq (ticker: EYEN).

## Customer and partnership activity
Eyenovia is pursuing partnerships with healthcare institutions and conducting clinical trials to support product development and potential commercialization.

## Conclusion
Eyenovia is positioned within the ophthalmic therapeutics sector, developing microdose-based eye care solutions. As the company advances through clinical programs, it intends to move toward commercialization and broaden access to its treatments.

EYENOVIA, INC.

10-K / April 30, 2025

10-K / April 26, 2024

10-K / April 30, 2025

Company Summary: Eyenovia, Inc.

Overview

Business Focus

Financial and Operational Highlights (based on filing data, not recent or forward-looking)

Corporate Structure and Management

Notable Details